ヒト女性乳癌における男性ホルモン、アンドロゲンの局所産生と作用機序の解明

上述研究的结果表明，在TNBC样本中AR的表达与较低的增殖水平相关，并且这种关联在也表达雄激素合成途径的酶的样本中更强。这一结果实际上与我们最初的假设相反，根据其他人的研究报告，在缺乏雌激素受体的情况下，雄激素受体水平非常高的群体预后更差，而且与这一领域的优势群体的结果相反。这一发现的新颖性得到了这项研究的认可，这项研究在2012年国际科学会议ENDO2012的总统海报竞赛中获奖，导致被邀请在2012年在金泽举行的关于激素类固醇和激素与癌症的第15届国际大会上发言，并随后发表在癌症科学杂志上。自从这个最初相互矛盾的发现以来，我们一直在寻找可能的解释，以协调总体趋势，病理分析显示雄激素受体是潜在的增殖抑制因子，而细胞系和分子分析表明雄激素受体是潜在的癌基因。目前正在考虑发表在《乳腺癌研究与治疗》杂志上的最新数据表明，在三阴性乳腺癌中，可能至少有两种不同类型的AR表达TNBC。结合最近来自其他小组的两份报告，这可能为选择AR靶向药物作为TNBC的治疗方法时患者的选择提供重要信息。此外，最近的论文表明ERβ在乳腺癌中的作用，再加上雄激素受体和ERβ受体配体之间的已知重叠，导致了研究TNBC中这些因素的项目的扩大。

Results of the research above revealed that AR expression in TNBC specimens correlated with lower levels of proliferation and this association was stronger in samples that also expressed enzymes for androgen synthetic pathways. This result was actually contrary to our original hypothesis, based on the research reports from others that groups characterized by very high levels of androgen receptor in the absence of estrogen receptor had a worse prognosis, and is contrary to the results of the dominate group in this area of research. The novelty of this finding was recognized by the research being awarded a prize in the presidential poster competition at the international scientific meeting ENDO2012, lead to an invitation to speak at the 15^<th> International congress on hormonal steroid and hormones & cancer in Kanazawa in 2012 and was subsequently published in the journal cancer science. Since this original contradictory finding we have been searching through possible explanations that reconcile an overall trend showing the pathological analysis reveals the androgen receptor to be a potential suppressor of proliferation, yet cell line and molecular analysis suggesting the androgen receptor as a potential oncogene. Recent data, currently under consideration for publication in the journal breast cancer research and treatment suggests that in triple negative breast cancer there may be at least two distinct types of AR expressing TNBC. In tandem with two recent reports from other groups this may provide important information in patient selection when choosing AR targeting agents as a therapy in TNBC. In addition to this, recent papers suggesting a role of ERβ in breast cancer, combined with the known overlap between androgen receptor and ERβ receptor ligands has led to an expansion of the project to investigate these factors in TNBC.